GABA(B) receptors in neuroendocrine regulation. 2008

Victoria A Lux-Lantos, and María S Bianchi, and Paolo N Catalano, and Carlos Libertun
Laboratory of Neuroendocrinology, Instituto de Biología y Medicina Experimental-CONICET, V. de Obligado 2490, C1428ADN, Buenos Aires, Argentina.

Gamma-amino butyric acid (GABA), in addition to being a metabolic intermediate and the main inhibitory neurotransmitter in the synaptic cleft, is postulated as a neurohormone, a paracrine signaling molecule, and a trophic factor. It acts through pre- and post-synaptic receptors, named GABA(A) and GABA(C) (ionotropic receptors) and GABA(B) (metabotropic receptor). Here we reviewed the participation of GABA(B) receptors in the regulation of the hypothalamic-pituitary-gonadal axis, using physiological, biochemical, and pharmacological approaches in rats, as well as in GABA(B1) knock-out mice, that lack functional GABA(B) receptors. Our general conclusion indicates that GABA(B )receptors participate in the regulation of pituitary hormone secretion acting both in the central nervous system and directly on the gland. PRL and gonadotropin axes are affected by GABA(B) receptor activation, as demonstrated in the rat and also in the GABA(B1) knock-out mouse. In addition, hypothalamic and pituitary GABA(B) receptor expression is modulated by steroid hormones. GABA participation in the brain control of pituitary secretion through GABA(B) receptors depends on physiological conditions, being age and sex critical factors.These results indicate that patients receiving GABA(B) agonists/antagonists should be monitored for possible endocrine side effects.

UI MeSH Term Description Entries
D007030 Hypothalamo-Hypophyseal System A collection of NEURONS, tracts of NERVE FIBERS, endocrine tissue, and blood vessels in the HYPOTHALAMUS and the PITUITARY GLAND. This hypothalamo-hypophyseal portal circulation provides the mechanism for hypothalamic neuroendocrine (HYPOTHALAMIC HORMONES) regulation of pituitary function and the release of various PITUITARY HORMONES into the systemic circulation to maintain HOMEOSTASIS. Hypothalamic Hypophyseal System,Hypothalamo-Pituitary-Adrenal Axis,Hypophyseal Portal System,Hypothalamic-Pituitary Unit,Hypothalamic Hypophyseal Systems,Hypothalamic Pituitary Unit,Hypothalamo Hypophyseal System,Hypothalamo Pituitary Adrenal Axis,Portal System, Hypophyseal
D009490 Neurosecretory Systems A system of NEURONS that has the specialized function to produce and secrete HORMONES, and that constitutes, in whole or in part, an ENDOCRINE SYSTEM or organ. Neuroendocrine System,Neuroendocrine Systems,Neurosecretory System,System, Neuroendocrine,System, Neurosecretory,Systems, Neuroendocrine,Systems, Neurosecretory
D010907 Pituitary Hormones Hormones secreted by the PITUITARY GLAND including those from the anterior lobe (adenohypophysis), the posterior lobe (neurohypophysis), and the ill-defined intermediate lobe. Structurally, they include small peptides, proteins, and glycoproteins. They are under the regulation of neural signals (NEUROTRANSMITTERS) or neuroendocrine signals (HYPOTHALAMIC HORMONES) from the hypothalamus as well as feedback from their targets such as ADRENAL CORTEX HORMONES; ANDROGENS; ESTROGENS. Hormones, Pituitary
D010913 Pituitary-Adrenal System The interactions between the anterior pituitary and adrenal glands, in which corticotropin (ACTH) stimulates the adrenal cortex and adrenal cortical hormones suppress the production of corticotropin by the anterior pituitary. Pituitary Adrenal System,Pituitary-Adrenal Systems,System, Pituitary-Adrenal,Systems, Pituitary-Adrenal
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018080 Receptors, GABA-B A subset of GABA RECEPTORS that signal through their interaction with HETEROTRIMERIC G-PROTEINS. Baclofen Receptors,GABA-B Receptors,Baclofen Receptor,GABA receptor rho1,GABA type B receptor, subunit 1,GABA(B)R1,GABA(B)R1 receptor,GABA(B)R1a protein,GABA(B)R1a receptor,GABA(B)R1b protein,GABA(B)R1b receptor,GABA-B Receptor,GABBR1 protein,GB1a protein,GB1b protein,GBR1B protein,Receptors, Baclofen,rho1 subunit, GABA receptor
D018345 Mice, Knockout Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes. Knockout Mice,Mice, Knock-out,Mouse, Knockout,Knock-out Mice,Knockout Mouse,Mice, Knock out

Related Publications

Victoria A Lux-Lantos, and María S Bianchi, and Paolo N Catalano, and Carlos Libertun
March 2001, Neuroreport,
Victoria A Lux-Lantos, and María S Bianchi, and Paolo N Catalano, and Carlos Libertun
January 2010, Advances in pharmacology (San Diego, Calif.),
Victoria A Lux-Lantos, and María S Bianchi, and Paolo N Catalano, and Carlos Libertun
May 2005, European journal of pharmacology,
Victoria A Lux-Lantos, and María S Bianchi, and Paolo N Catalano, and Carlos Libertun
January 2008, Results and problems in cell differentiation,
Victoria A Lux-Lantos, and María S Bianchi, and Paolo N Catalano, and Carlos Libertun
July 2023, JCI insight,
Victoria A Lux-Lantos, and María S Bianchi, and Paolo N Catalano, and Carlos Libertun
January 2008, Pharmacological reports : PR,
Victoria A Lux-Lantos, and María S Bianchi, and Paolo N Catalano, and Carlos Libertun
June 2008, The European journal of neuroscience,
Victoria A Lux-Lantos, and María S Bianchi, and Paolo N Catalano, and Carlos Libertun
October 2006, Neuroscience,
Victoria A Lux-Lantos, and María S Bianchi, and Paolo N Catalano, and Carlos Libertun
January 1987, Neurochemistry international,
Victoria A Lux-Lantos, and María S Bianchi, and Paolo N Catalano, and Carlos Libertun
October 2001, Molecular interventions,
Copied contents to your clipboard!